Pabitra Basnyat1, Sanna Hagman2, Marcin Kolasa1, Keijo Koivisto3, Auli Verkkoniemi-Ahola4, Laura Airas5, Irina Elovaara6. 1. Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland. 2. Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland. Electronic address: sanna.hagman@uta.fi. 3. Seinäjoki Central Hospital, Department of Neurology, Seinäjoki, Finland. 4. Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland. 5. Department of Clinical Neurosciences, Turku University Hospital, Turku, Finland. 6. Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland; Department of Neurology, Tampere University Hospital, Tampere, Finland.
Abstract
OBJECTIVE: In relapsing-remitting MS (RRMS) patients treated with natalizumab, the low level of L-selectin-expressing CD4+ T cells has been associated with the risk of progressive multifocal leukoencephalopathy (PML). In this study, our aim was to correlate the levels of soluble L-selectin and the anti-JCV antibody index in the sera of RRMS patients treated with natalizumab. METHODS: This study included 99 subjects, including 44 RRMS patients treated with natalizumab, 30 with interferon beta (IFN-β) and 25 healthy controls. The levels of soluble L-selectin (sL-selectin) in sera were measured by ELISA, and the anti-JC Virus (JCV) antibody index was determined by the second-generation ELISA (STRATIFY JCV™ DxSelect™) assay. RESULTS: A significant correlation was found between the levels of sL-selectin and anti-JCV antibody indices in sera in the natalizumab-treated patients (r=0.402; p=0.007; n=44), but not in those treated with IFN-β. This correlation became even stronger in JCV seropositive patients treated with natalizumab for longer than 18 months (r=0.529; p=0.043; n=15). CONCLUSION: The results support the hypothesis of sL-selectin being connected to the anti-JCV antibody index values and possibly cellular L-selectin. Measurement of serum sL-selectin should be evaluated further as a potential biomarker for predicting the risk of developing PML.
OBJECTIVE: In relapsing-remitting MS (RRMS) patients treated with natalizumab, the low level of L-selectin-expressing CD4+ T cells has been associated with the risk of progressive multifocal leukoencephalopathy (PML). In this study, our aim was to correlate the levels of soluble L-selectin and the anti-JCV antibody index in the sera of RRMS patients treated with natalizumab. METHODS: This study included 99 subjects, including 44 RRMS patients treated with natalizumab, 30 with interferon beta (IFN-β) and 25 healthy controls. The levels of soluble L-selectin (sL-selectin) in sera were measured by ELISA, and the anti-JC Virus (JCV) antibody index was determined by the second-generation ELISA (STRATIFY JCV™ DxSelect™) assay. RESULTS: A significant correlation was found between the levels of sL-selectin and anti-JCV antibody indices in sera in the natalizumab-treated patients (r=0.402; p=0.007; n=44), but not in those treated with IFN-β. This correlation became even stronger in JCV seropositive patients treated with natalizumab for longer than 18 months (r=0.529; p=0.043; n=15). CONCLUSION: The results support the hypothesis of sL-selectin being connected to the anti-JCV antibody index values and possibly cellular L-selectin. Measurement of serum sL-selectin should be evaluated further as a potential biomarker for predicting the risk of developing PML.
Authors: Martyn K White; Ilker K Sariyer; Jennifer Gordon; Serena Delbue; Valeria Pietropaolo; Joseph R Berger; Kamel Khalili Journal: Rev Med Virol Date: 2015-12-14 Impact factor: 6.989
Authors: Margarete Maria Voortman; Paul Greiner; Daniel Moser; Martin Helmut Stradner; Winfried Graninger; Adrian Moser; Bernd Haditsch; Christian Enzinger; Siegrid Fuchs; Franz Fazekas; Johannes Fessler; Michael Khalil Journal: Mult Scler J Exp Transl Clin Date: 2018-09-20